Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.37 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.37 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GNRHR | P30968 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4766006 | 0.90 | PDE4A (0.44) | PDE4AADORA3P2RX3HSPD1HSPE1 | |
| SCHEMBL4769402 | 0.86 | POLB (0.43) | P2RX3HSPD1HSPE1KMT2AALDH1A1 | |
| SCHEMBL4769603 | 0.84 | DCTPP1 (0.46) | ADORA3P2RX3KMT2AMEN1ALDH1A1 | |
| SCHEMBL4770944 | 0.83 | ADORA2A (0.39) | HTTALDH1A1ADORA2AADORA2BPOLB | |
| SCHEMBL4771305 | 0.83 | HTT (0.44) | PDE4AHSPD1HSPE1KMT2AMEN1 | |
| SCHEMBL4766297 | 0.81 | HSPD1 (0.36) | ADORA3ADORA1HSPD1HSPE1KMT2A | |
| SCHEMBL4767937 | 0.81 | PDE4A (0.46) | PDE4AADORA3HSPD1HSPE1KMT2A | |
| SCHEMBL4766012 | 0.81 | PDE4A (0.38) | PDE4AADORA3P2RX3HSPD1HSPE1 | |
| SCHEMBL4763645 | 0.78 | SIRT1 (0.40) | ADORA1KMT2AHTTALDH1A1ADORA2A | |
| SCHEMBL4765585 | 0.76 | MAPT (0.44) | HSPD1HSPE1KMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | PDE4A 182/4885ADORA3 3/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.